For what concerns immunotherapy, Pilanc et al. [214] showed that combining an anti-PD1 antibody and arginase 1/2 inhibitor OAT-1746 in U87 and LN18 glioma cell lines appeared to potentiate PD1 blockade and inhibit tumor growth in glioma murine models. Here, ARG1 is linked to glioma.